close
Total Points: 100
close
Edit Partner Bio
close
Add Position
close
Add Education
close
Profile
close
Profile
close
Partner Description
close
FOLLOWERS ()
close
Edit your post
close
EDIT APPLICATION
close
Start a Talk
Share articles, books, podcasts, ideas or questions that you think are important for other professionals to stay fresh and relevant.
close
Mark Robertson
Founder and Director, Science Policy Compass Ltd. at Science Policy Compass Ltd.
Comments
Keep the conversation going
Mark Robertson
Founder and Director, Science Policy Compass Ltd. at Science Policy Compass Ltd.
Joined 07/31/2017
Level: LEVEL 01 (12 mo pts: 0 pts)
Lifetime points: 100 pts
Mark is Founder and Director of a new start-up, Science Policy Compass Ltd. offering science policy / bioethics support and advice important to the bioscience sector. The establishment of a high quality ethical reputation is an essential component to make any science activity attractive in the eyes of investors, collaborators and the general public. Company website: www.sciencepolicycompass.co.uk; Contact Mark at: mark@sciencepolicycompass.co.uk
Until August 2016, Mark was Director in the Global Policy & Corporate Responsibility team in Corporate Affairs, AstraZeneca with 7 years dedicated science policy experience. As Chair of the AstraZeneca Bioethics Advisory Group (August 2014 - August 2016), responsible for evolving the AstraZeneca Global Bioethics Policy which included company guidance on the Nagoya Protocol; access to human biological samples for use in research; big data and data privacy; precise genome editing; clinical trials transparency and quality.
Educated at Southampton University, UK and University of Chicago, USA, Mark is a PhD pharmacologist (>50 peer-reviewed publications) and with 30 years Pharma experience mostly in novel medicine project delivery (e.g. 7 years as section manager of Astra pre-clinical team that conceived the principle of and discovered the anti-thrombotic agents, Brilinta and Cangrelor). Worked in several Pharma (including 10 years at GSK), disease areas and business models. Astra/Zeneca corporate merger team member 1999-2000.
In the past 7 years, Mark has specialised on science policy and bioethics. His current interest areas include: Responsible Business and corporate sustainability; corporate reputation, precise genome editing /gene therapy ethics; synthetic biology; chimeras; Nagoya Protocol /biodiversity /access and benefit sharing; clinical trial transparency and quality, donor and patient consent/ data privacy, transparent access to human biological samples for research use.
Until August 2016, Mark was Director in the Global Policy & Corporate Responsibility team in Corporate Affairs, AstraZeneca with 7 years dedicated science policy experience. As Chair of the AstraZeneca Bioethics Advisory Group (August 2014 - August 2016), responsible for evolving the AstraZeneca Global Bioethics Policy which included company guidance on the Nagoya Protocol; access to human biological samples for use in research; big data and data privacy; precise genome editing; clinical trials transparency and quality.
Educated at Southampton University, UK and University of Chicago, USA, Mark is a PhD pharmacologist (>50 peer-reviewed publications) and with 30 years Pharma experience mostly in novel medicine project delivery (e.g. 7 years as section manager of Astra pre-clinical team that conceived the principle of and discovered the anti-thrombotic agents, Brilinta and Cangrelor). Worked in several Pharma (including 10 years at GSK), disease areas and business models. Astra/Zeneca corporate merger team member 1999-2000.
In the past 7 years, Mark has specialised on science policy and bioethics. His current interest areas include: Responsible Business and corporate sustainability; corporate reputation, precise genome editing /gene therapy ethics; synthetic biology; chimeras; Nagoya Protocol /biodiversity /access and benefit sharing; clinical trial transparency and quality, donor and patient consent/ data privacy, transparent access to human biological samples for research use.
close
Edit your Comment